Medicare Part D appeals after a drug coverage denial

A beneficiary who receives an unfavorable Medicare Part D coverage determination may appeal through five successive levels, beginning with plan-sponsor redetermination and then an independent review. Standard and expedited requests have different decision timeframes.

Start with the decision notice

A Part D plan’s adverse coverage determination should explain the decision and the beneficiary’s appeal rights. The notice matters because it identifies the reason for denial, how to request review, and where to send the request. An enrollee, prescriber, or appointed representative may request a redetermination by the plan sponsor. A pharmacy claim rejection may not yet be a formal adverse coverage determination; when needed, the patient or prescriber can ask the plan to make one. This creates a decision that can be appealed. Pharmacy staff should preserve the claim response and direct the patient to the plan rather than treating a reject code as the last word.

The five levels

Part D has five successive appeal levels: redetermination by the Part D plan sponsor; reconsideration by an Independent Review Entity; a hearing before an Administrative Law Judge; review by the Medicare Appeals Council; and judicial review in federal district court if statutory thresholds and other requirements are met. A beneficiary normally proceeds to the next level only after an unfavorable decision at the preceding level. The notice at each stage explains how to continue. This is different from the five levels in Original Medicare Part A and Part B appeals, even though some labels sound similar. For Part D, the first redetermination is handled by the plan sponsor, not a Medicare Administrative Contractor.

Requesting a redetermination

A request generally must be filed within 65 calendar days from the date of the plan’s coverage-determination notice. The plan may extend the deadline for good cause under applicable rules. Standard requests are generally written, though a plan may accept them verbally; expedited requests can be made verbally or in writing. The request should identify the enrollee, drug, denial, and reason the decision should change. For a formulary or tiering exception denial, include the prescriber’s clinical support when needed. Keep proof of when the request was submitted. If the patient’s health could be seriously jeopardized by waiting, tell the plan that an expedited decision is requested and explain the urgency.

Decision timeframes

The plan must decide a standard redetermination request for a benefit as expeditiously as the enrollee’s health requires and generally no later than seven calendar days after receipt. An expedited redetermination is generally due within 72 hours. A payment request has a separate 14-calendar-day timeframe. If the plan fails to decide within the applicable deadline, the request is forwarded for independent review under the program rules. A verbal expedited decision may be followed by a written notice. Timeframes can be shorter where the plan’s process allows, but the patient should rely on the current notice and CMS guidance. Do not confuse the initial coverage determination timeframe with the appeal deadline.

Independent review and later steps

If the plan upholds its denial, the notice explains how to request reconsideration by the Independent Review Entity (IRE). The IRE is independent of the plan sponsor. An unfavorable IRE decision may be followed by an ALJ hearing if the amount-in-controversy and filing requirements are met; further review proceeds to the Medicare Appeals Council and, when permitted, federal court. At each level, use the notice for the current deadline and submission address. The beneficiary may submit medical records or a prescriber’s statement that addresses the denial reason. The pharmacy’s dispensing record may help document urgency or an alternative tried, but the prescriber is best placed to explain clinical necessity.

Exception request versus appeal

An exception request is part of the initial coverage-determination process. An appeal challenges an unfavorable coverage determination after the plan has issued it. If the patient has not yet asked the plan to decide whether a non-formulary drug should be covered, begin with a coverage determination/exception, not a redetermination appeal. If the plan has denied that request, the next step is the appeal described in the notice. A claim override performed by the pharmacy does not replace either process. Identify the stage before advising the patient; using the wrong form or address can delay access.

How pharmacy staff can support the patient

The pharmacist can explain the general process, identify the specific claim barrier, coordinate with the prescriber, and provide documentation the patient may need. A technician can tell the patient that the plan issued a rejection, obtain the plan’s contact details, and route clinical questions to the pharmacist. Neither should promise approval or give a clinical substitute without proper authorization. When a patient has an urgent dose due, escalate immediately to the pharmacist and prescriber. Ask whether an expedited determination is appropriate and whether an alternative can be safely supplied. Document communication and follow-up in the pharmacy system according to policy.

A practical verification point

An expedited request is appropriate when waiting for the standard process could seriously jeopardize the enrollee’s life, health, or ability to regain maximum function under the applicable Medicare standard. The plan determines whether it qualifies, but the request should state the urgency and include supporting clinical information. If the patient’s condition is stable and no urgent risk is identified, the standard timeframe generally applies. Staff should record the date of the notice and submission so the appeal window can be tracked accurately.

How to approach an exam scenario

Start by identifying the specific rule, medication phase, or coverage stage in the question. Separate what a technician can collect and document from the pharmacist’s clinical or legal decision. Apply the rule to the dates, order details, and authorized workflow provided. When a detail varies by state or by product, use the current primary source and escalate rather than making an assumption.